Ivosidenib is a medication that belongs to a class of drugs known as IDH1 inhibitors. It is used in the treatment of certain types of acute myeloid leukemia (AML) in adults who have a specific genetic mutation known as IDH1. This mutation causes the production of an abnormal protein that can lead to the development of AML.

Ivosidenib works by targeting and inhibiting the activity of the mutated IDH1 protein, which helps to slow down the growth and spread of cancer cells. By blocking this protein, Ivosidenib can help to induce remission and improve overall survival in patients with IDH1-mutated AML.

It is important to note that Ivosidenib is not a cure for AML, but it can be a valuable treatment option for patients with this specific genetic mutation. Like all medications, Ivosidenib may cause side effects, which can vary from person to person. Common side effects may include nausea, diarrhea, fatigue, and changes in liver function tests.

As a medical professional, it is important to discuss the potential benefits and risks of Ivosidenib with your patients, and to closely monitor them for any signs of side effects or complications. It is also important to ensure that patients are receiving appropriate supportive care while taking Ivosidenib, such as managing symptoms and monitoring blood counts.

Overall, Ivosidenib is a promising treatment option for patients with IDH1-mutated AML, and can play a valuable role in their overall care and management. By staying informed and working closely with patients, we can help to optimize the use of Ivosidenib and improve outcomes for individuals with this challenging disease.